<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>The main drug classes used as potential treatments in COVID-19.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Drug</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Class</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Rationale use</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Clinical experience</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Observations</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">(Hydroxy)chloroquine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antimalarial</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Changes the pH of the cell membrane surface and thus inhibits the fusion of the virus with the cell membrane. Inhibits nucleic acid replication, glycosylation of viral proteins, assembly of the virus, and release of the virus from the infected cell.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <italic>In vitro</italic> activity against SARS-CoV-2, as well as some positive results in the treatment of patients with COVID-19 (
     <xref rid="B32" ref-type="bibr">32</xref>). A recent study showed faster virus clearance in patients with COVID-19 who received hydroxychloroquine (
     <xref rid="B33" ref-type="bibr">33</xref>). Initial dose: 600 mg (of chloroquine) followed by 300 mg (of chloroquine) 12 h later on day 1, then 300 mg (of chloroquine) twice daily on days 2–5.
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">It has been widely used in long-term treatments in rheumatology, without generating significant side effects.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Camostat</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibits TMPRSS2 protease</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibition of cell entry Prevents SARS-CoV-2 coronavirus infection</td>
    <td valign="top" align="left" rowspan="1" colspan="1">An 
     <italic>in vitro</italic> study in a mouse model demonstrated the efficacy of camostat in protecting mice from death from a lethal SARS-CoV infection with a 60% survival rate (
     <xref rid="B34" ref-type="bibr">34</xref>). It is considered that doses of 600 mg (200 mg, three times) of camostat daily are expected to reduce SARS-CoV-2 infection; but human clinical trials are needed (
     <xref rid="B35" ref-type="bibr">35</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Mesylate camostat, approved in the treatment of inflammation of the pancreas in Japan.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antiviral for Ebola</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Inhibits RNA-dependent RNA polymerase, prematurely blocking RNA transcription.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Broad antiviral spectrum; Efficacy against coronaviruses, both 
     <italic>in vitro</italic> and 
     <italic>in vivo</italic> studies; The safety profile has been demonstrated in Ebola studies; Superior efficacy of the Lopinavir/Ritonavir/IFNbeta combination in animal model studies. Adults and children weighing 40 kg or more: Loading dose of 200 mg by IV infusion on day 1, followed by 100 mg by IV infusion once daily on days 2–10 or followed by 100 mg by IV infusion once daily on days 2–5.
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">FDA (US) has authorized the use of remdesivir in severe infection with the new coronavirus SARS-CoV-2, through the Special Emergency Use Authorization (EUA).</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir /Ritonavir (LPV/RTV) combination</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antiviral for HIV</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir is a protease inhibitor used to treat HIV infection in combination with ritonavir to increase its availability.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Lopinavir has some degree of activity against coronaviruses 
     <italic>in vitro</italic>, including SARS-CoV-2. The clinical data published so far have been inconsistent. Three observational studies failed to identify a reduction in the duration of virus excretion in patients treated with lopinavir/ritonavir compared to favipiravir or placebo, while during the Wuhan epidemic the use of lopinavir/ritonavir resulted in faster elimination of the virus. In the case of early administration, in the initial viral phase, in the first 10 days after the onset of symptoms (
     <xref rid="B36" ref-type="bibr">36</xref>). LPV/RTV (COVID-19): LPV 400 mg/RTV 100 mg orally twice daily for 10–14 days (
     <xref rid="B37" ref-type="bibr">37</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">This drug remains as another alternative, in the absence of more effective drugs. An additional plus is related to the form of liquid administration—usable in orotracheal intubated patients and in newborns.</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Umifenovir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antiviral for influenza viruses</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Blocking the penetration of the virus into cells (fusion inhibitor) and the immunomodulatory effect.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">In patients with uncomplicated pneumonia in COVID-19, the combination of umifenovir (200 mg every 8 h) with lopinavir/ritonavir resulted in faster clearance of the virus at the nasopharyngeal level and a faster regression of lung imaging changes compared to patients receiving monotherapy with lopinavir/ritonavir (
     <xref rid="B38" ref-type="bibr">38</xref>). 200 mg orally 3 times daily for duration of 7–10 days or longer (
     <xref rid="B39" ref-type="bibr">39</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Reduced side effects</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Antiviral for flu and Ebola</td>
    <td valign="top" align="left" rowspan="1" colspan="1">RNA polymerase inhibitor</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Used in China in patients of childbearing potential only if they had a negative pregnancy test and always associated with contraceptive medication during treatment and at least 7 days after stopping treatment; Doses: 1,600 mg every 12 h on the first day, then 600 mg every 12 h for 7–14 days. The drug cannot be administered to children and pregnant women (teratogenic risk)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Teratogenic effects</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Immunomodulatory</td>
    <td valign="top" align="left" rowspan="1" colspan="1">IL-6 receptor antagonist</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Has been used in a subset of patients with severe COVID-19 in whom there is excessive activation of inflammation (“cytokine storm”). The effectiveness of tocilizumab has been shown in small groups of patients; after administration of 1–2 doses, afebrility was obtained in all patients, as well as a decrease in oxygen requirements and partial correction of lymphopenia. The results obtained with tocilizumab combined with corticosteroids were favorable, following the administration of doses of 8 mg/kgc, repeated at 8–12 h, up to a maximum of 3 administrations (
     <xref rid="B40" ref-type="bibr">40</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Risks associated with the reactivation of tuberculosis, hepatic cytolysis, hypercholesterolemia.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
